Vertex Pharmaceuticals Incorporated is a biopharmaceutical company based in Boston, Massachusetts, with around 2,500 employees. Founded in 1989 by Joshua Boger and Kevin J. Kinsella, Vertex aims to transform the treatment of serious diseases. The company is recognized for its innovative approach to drug design, focusing on rational drug design rather than combinatorial chemistry. Vertex is best known for its therapies for cystic fibrosis, including Kalydeco, Lumacaftor, and tezacaftor. The company has also developed Incivek, a hepatitis C treatment. Vertex's current research pipeline targets specialty diseases such as sickle cell disease, beta thalassemia, and Duchenne muscular dystrophy. Additionally, Vertex has made significant investments in developing diabetes treatments and gene-editing therapies through collaborations and acquisitions.